CytomX therapeutics general counsel sells $6,111 in stock

Published 20/03/2025, 21:36
CytomX therapeutics general counsel sells $6,111 in stock

Following the sale, Lloyd retains direct ownership of 120,594 shares, which includes 30,624 restricted stock units (RSUs). The shares were sold to satisfy tax or other government withholding obligations related to the vesting of RSUs. The transaction occurs as CytomX maintains a strong financial position with more cash than debt on its balance sheet, and analysts have recently revised their earnings expectations upward. Discover more insights about CTMX and access comprehensive analysis of 1,400+ stocks with a InvestingPro subscription. The transaction occurs as CytomX maintains a strong financial position with more cash than debt on its balance sheet, and analysts have recently revised their earnings expectations upward. Discover more insights about CTMX and access comprehensive analysis of 1,400+ stocks with a InvestingPro subscription.

Following the sale, Lloyd retains direct ownership of 120,594 shares, which includes 30,624 restricted stock units (RSUs). The shares were sold to satisfy tax or other government withholding obligations related to the vesting of RSUs.

In other recent news, CytomX Therapeutics Inc (NASDAQ:CTMX). reported its fourth-quarter 2024 financial results, showcasing a remarkable revenue achievement. The company reported a total revenue of $138.1 million, significantly surpassing the forecast of $12.24 million. This impressive performance is primarily attributed to successful collaborations with major partners, including Bristol Myers (NYSE:BMY) Squibb, Moderna (NASDAQ:MRNA), Astellas, and Regeneron (NASDAQ:REGN). Additionally, CytomX has extended its cash runway to the second quarter of 2026, providing a solid financial foundation for future operations. However, the company has faced challenges, such as the discontinuation of the CX-9004 program with Amgen (NASDAQ:AMGN), which may impact future revenue streams. Despite these challenges, CytomX is optimistic about its ongoing clinical programs, notably CX-2051 and CX-8001, which are progressing well. The company plans to release initial Phase 1a data for CX-2051 in the first half of 2025 and initiate a combination study of CX-8001 with KEYTRUDA later that year. These developments reflect CytomX’s strategic focus on advancing its therapeutic pipeline and addressing unmet needs in oncology.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.